Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes
Mellitus

J 2015

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

KATUCHOVA, Jana, Denisa HARVANOVA, Timea SPAKOVA, Rastislav KALANIN, Daniel FARKAS et. al.

Basic information

Original name

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

Authors

KATUCHOVA, Jana (703 Slovakia), Denisa HARVANOVA (703 Slovakia), Timea SPAKOVA (703 Slovakia), Rastislav KALANIN (703 Slovakia), Daniel FARKAS (703 Slovakia), Peter DURNY (703 Slovakia), Jan ROSOCHA (703 Slovakia), Jozef RADONAK (703 Slovakia), Daniel PETROVIC (705 Slovenia), Dario SINISCALCO (380 Italy), Meirigeng QI (840 United States of America), Miroslav NOVÁK (203 Czech Republic, belonging to the institution) and Peter KRUŽLIAK (203 Czech Republic, guarantor)

Edition

Endocrine Pathology, Totowa, Humana Press INC, 2015, 1046-3976

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.817

RIV identification code

RIV/00216224:14110/15:00085444

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s12022-015-9362-y

UT WoS

000354617600001

Keywords in English

Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells

Abstract

V originále

Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.

Citovat

KATUCHOVA, Jana, Denisa HARVANOVA, Timea SPAKOVA, Rastislav KALANIN, Daniel FARKAS, Peter DURNY, Jan ROSOCHA, Jozef RADONAK, Daniel PETROVIC, Dario SINISCALCO, Meirigeng QI, Miroslav NOVÁK and Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. Endocrine Pathology. Totowa: Humana Press INC, 2015, vol. 26, No 2, p. 95-103. ISSN 1046-3976. Available from: https://dx.doi.org/10.1007/s12022-015-9362-y.

@article{1322325,
   author = {Katuchova, Jana and Harvanova, Denisa and Spakova, Timea and Kalanin, Rastislav and Farkas, Daniel and Durny, Peter and Rosocha, Jan and Radonak, Jozef and Petrovic, Daniel and Siniscalco, Dario and Qi, Meirigeng and Novák, Miroslav and Kružliak, Peter},
   article_location = {Totowa},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s12022-015-9362-y},
   keywords = {Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells},
   language = {eng},
   issn = {1046-3976},
   journal = {Endocrine Pathology},
   title = {Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus},
   volume = {26},
   year = {2015}
}

TY  - JOUR
ID  - 1322325
AU  - Katuchova, Jana - Harvanova, Denisa - Spakova, Timea - Kalanin, Rastislav - Farkas, Daniel - Durny, Peter - Rosocha, Jan - Radonak, Jozef - Petrovic, Daniel - Siniscalco, Dario - Qi, Meirigeng - Novák, Miroslav - Kružliak, Peter
PY  - 2015
TI  - Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus
JF  - Endocrine Pathology
VL  - 26
IS  - 2
SP  - 95-103
EP  - 95-103
PB  - Humana Press INC
SN  - 10463976
KW  - Diabetes type 1
KW  - Mesenchymal stem cells
KW  - Insulin
KW  - Islet-producing cells
N2  - Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.
ER  -

KATUCHOVA, Jana, Denisa HARVANOVA, Timea SPAKOVA, Rastislav KALANIN, Daniel FARKAS, Peter DURNY, Jan ROSOCHA, Jozef RADONAK, Daniel PETROVIC, Dario SINISCALCO, Meirigeng QI, Miroslav NOVÁK and Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. \textit{Endocrine Pathology}. Totowa: Humana Press INC, 2015, vol.~26, No~2, p.~95-103. ISSN~1046-3976. Available from: https://dx.doi.org/10.1007/s12022-015-9362-y.

Detailed Information on Publication Record